Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study ID
- NCT07365709
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cirrhosis
- Portal Hypertension
- Spleen Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SonoVue — DRUGmicrobubbles infusion and ultrasound
Study Details
Portal hypertension is a major complication of cirrhosis. HVPG is the diagnostic gold standard but is invasive. Non-invasive tools such as spleen stiffness measurement (SSM) and CEUS show promise for assessing CSPH, though they have not yet been compared directly. A multimodal ultrasound approach may provide a reliable alternative to HVPG.
Key Dates
- First listed
- Jan 26, 2026
- Start date
- Feb 1, 2026
- Status verified
- Jan 2026
- Primary completion
- Jul 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 107 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: CirrhosisAdult participants (≥18 years old) with clinically confirmed liver cirrhosis, classified as Child-Pugh class A-C, with clinical and morphological signs of portal hypertension
Primary Outcome Measure
Primary endpoint [ Time Frame: 12 months ]
Central Contacts
- Fabrizio Pizzolante, MD Phd+390630159650
Related Studies
- Blood Collection Biorepository for Liver Disease ResearchRecruiting · State University of New York at Buffalo · Buffalo, New York
- Mechanisms of Malnutrition in Cirrhosis With Portosystemic ShuntingRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Novel Tracer Methods to Evaluate Muscle Protein Metabolism in CirrhosisRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Safety and Efficacy of Atorvastatin v. Placebo on HCC RiskPHASE2 · Recruiting · Raymond Chung · Boston, Massachusetts